Ryan Schafer, DO
Family Medicine · Ardmore, OKNPI 1780650606
Payments from drug & device makers
Across 212 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$714
- Lilly USA, LLC$522
- Takeda Pharmaceuticals U.S.A., Inc.$447
- Pfizer$306
- Johnson & Johnson$224
- Boston Scientific$137
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,565100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $714 |
| Lilly USA, LLC | 38 | $522 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $447 |
| Pfizer | 22 | $306 |
| Johnson & Johnson | 6 | $224 |
| Boston Scientific | 2 | $137 |
| Bayer | 8 | $133 |
| Collegium Pharmaceutical, Inc. | 8 | $123 |
| Pacira Therapeutics, Inc. | 5 | $112 |
| Alnylam Pharmaceuticals Inc. | 5 | $100 |
| Amgen | 6 | $96 |
| Phathom Pharmaceuticals, Inc. | 4 | $73 |
| AbbVie(2 entities) | 5 | $71 |
| AstraZeneca | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 5 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Eisai Inc. | 2 | $28 |
| Virtus Pharmaceuticals LLC | 2 | $28 |
| Merck | 2 | $27 |
| Novartis | 1 | $24 |
| Exact Sciences | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Mylan Specialty L.p. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
| Abbott | 1 | $12 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$117
How this compares
$3,571 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $149,147 |
| EliquisApixaban | 130 | $109,474 |
| TrulicityDulaglutide | 88 | $100,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $64,317 |
| MounjaroTirzepatide | 37 | $46,857 |
| JardianceEmpagliflozin | 30 | $41,126 |
| JanuviaSitagliptin Phosphate | 30 | $39,702 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $37,736 |
| OxycontinOxycodone Hcl | 27 | $33,058 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 927 | $30,997 |
| LinzessLinaclotide | 25 | $29,434 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $28,983 |
| FarxigaDapagliflozin Propanediol | 18 | $21,907 |
| MyrbetriqMirabegron | 19 | $17,463 |
| InvokanaCanagliflozin | 11 | $17,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $714 | $149,147112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $522 | $147,773125 claims |
| PfizerEliquis, Premarin | $306 | $116,296148 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $12 | $82,130123 claims |
| MerckJanuvia, Janumet | $27 | $45,91641 claims |
| Johnson & JohnsonInvokana, Xarelto | $224 | $31,11234 claims |
| AbbVieLinzess | $71 | $29,43425 claims |
| AstraZenecaFarxiga, Symbicort | $70 | $27,37934 claims |
| BayerKerendia | $133 | $14,26318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $447 | $11,48017 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $123 | $8,72614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Ardmore
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.